US Patent 9925283 Alkylphosphocholine analogs for multiple myeloma imaging and therapy
Patent 9925283 was granted and assigned to Wisconsin Alumni Research Foundation on March, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Article (+209 characters)
Article
Patent abstract
It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula:
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09925283 Alkylphosphocholine analogs for multiple myeloma imaging and therapy US Patent 9925283 Alkylphosphocholine analogs for multiple myeloma imaging and therapy
Infobox
Patent Number
0992528300
Patent Number
992528300
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099252830
Date of Patent
March 27, 2018
0Patent Application Number
150956410
Date Filed
April 11, 2016
0Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099252830
Date of Patent
March 27, 2018
0Patent Application Number
150956410
Date Filed
April 11, 2016
0Patent Primary Examiner
Edits on 19 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09925283 Alkylphosphocholine analogs for multiple myeloma imaging and therapy
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09925283
Date of patent
March 27, 2018
Patent application number
15095641
Date Filed
April 11, 2016
Patent primary examiner
Find more entities like US Patent 9925283 Alkylphosphocholine analogs for multiple myeloma imaging and therapy
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.